EPIDERMOLYSIS BULLOSA, JUNCTIONAL
Clinical trials for EPIDERMOLYSIS BULLOSA, JUNCTIONAL explained in plain language.
Never miss a new study
Get alerted when new EPIDERMOLYSIS BULLOSA, JUNCTIONAL trials appear
Sign up with your email to follow new studies for EPIDERMOLYSIS BULLOSA, JUNCTIONAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New gel shows promise for rare skin disease in japanese patients
Disease control Recruiting nowThis study tests a gel called Oleogel-S10 on skin wounds in Japanese children and adults with two types of epidermolysis bullosa (EB), a genetic condition causing fragile skin. The main goal is to see if the gel can close wounds within 45 days and check for any side effects. Part…
Matched conditions: EPIDERMOLYSIS BULLOSA, JUNCTIONAL
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 26, 2026 10:27 UTC
-
Does a common EB gel raise or lower cancer risk? new 5-year study aims to find out.
Knowledge-focused Recruiting nowThis study follows about 580 people with a rare skin condition called epidermolysis bullosa (EB) for up to 5 years. Researchers want to see if using Filsuvez gel, which helps heal skin blisters, changes the chance of developing skin cancer. Participants receive standard care, and…
Matched conditions: EPIDERMOLYSIS BULLOSA, JUNCTIONAL
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated May 20, 2026 11:56 UTC